{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:30:09Z","timestamp":1792009809415,"version":"4.4.0"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Guangdong Medical University Undergraduate Innovation and Entrepreneurship Training Program","award":["GDMUCX2024101"],"award-info":[{"award-number":["GDMUCX2024101"]}]},{"name":"Guangdong Medical University Undergraduate Innovation and Entrepreneurship Education Base Project","award":["JDXM2024013"],"award-info":[{"award-number":["JDXM2024013"]}]},{"name":"Zhanjiang Non-funded Science and Technology Research Program Project","award":["2023B01177"],"award-info":[{"award-number":["2023B01177"]}]},{"name":"Clinical and Basic Sci&Tech Innovation of Guangdong Medical University","award":["GDMULCJC2024117"],"award-info":[{"award-number":["GDMULCJC2024117"]}]},{"name":"Guangdong Provincial Medical Science and Technology Research Fund","award":["A2025013"],"award-info":[{"award-number":["A2025013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11516-4","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T12:30:30Z","timestamp":1770208230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lineage plasticity: a new dilemma in lung cancer treatment"],"prefix":"10.1007","volume":"53","author":[{"given":"Cainan","family":"Huo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rujia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqi","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingke","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"issue":"3","key":"11516_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"11516_CR2","first-page":"620","volume":"73","author":"Z Megyesfalvi","year":"2023","unstructured":"Megyesfalvi Z et al (2023) Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin 73(6):620\u2013652","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"11516_CR3","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1038\/s41467-022-32052-2","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y et al (2022) Club cells employ regeneration mechanisms during lung tumorigenesis. Nat Commun 13(1):4557","journal-title":"Nat Commun"},{"issue":"10","key":"11516_CR4","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1158\/0008-5472.CAN-25-1177","volume":"85","author":"X Tong","year":"2025","unstructured":"Tong X, Lin G, Ji H (2025) Dr. Jekyll and Mr. Hyde: AT2 cells in lung regeneration and tumor development. Cancer Res 85(10):1753\u20131754","journal-title":"Cancer Res"},{"issue":"6752","key":"11516_CR5","doi-asserted-by":"publisher","first-page":"eads9145","DOI":"10.1126\/science.ads9145","volume":"388","author":"S G\u00f3mez-L\u00f3pez","year":"2025","unstructured":"G\u00f3mez-L\u00f3pez S et al (2025) Aberrant basal cell clonal dynamics shape early lung carcinogenesis. Science 388(6752):eads9145","journal-title":"Science"},{"issue":"6","key":"11516_CR6","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.ccr.2011.04.019","volume":"19","author":"KD Sutherland","year":"2011","unstructured":"Sutherland KD et al (2011) Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 19(6):754\u2013764","journal-title":"Cancer Cell"},{"issue":"6683","key":"11516_CR7","doi-asserted-by":"publisher","first-page":"eadj1415","DOI":"10.1126\/science.adj1415","volume":"383","author":"EE Gardner","year":"2024","unstructured":"Gardner EE et al (2024) Lineage-specific intolerance to oncogenic drivers restricts histological transformation. Science 383(6683):eadj1415","journal-title":"Science"},{"issue":"11","key":"11516_CR8","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41422-025-01180-x","volume":"35","author":"X Li","year":"2025","unstructured":"Li X et al (2025) Lineage plasticity and histological transformation: tumor histology as a spectrum. Cell Res 35(11):803\u2013823","journal-title":"Cell Res"},{"key":"11516_CR9","doi-asserted-by":"publisher","first-page":"175883592513690","DOI":"10.1177\/17588359251369038","volume":"17","author":"X Li","year":"2025","unstructured":"Li X et al (2025) Histologic transformation after targeted therapy resistance in driver gene-positive NSCLC: mechanisms and therapeutic challenges. Ther Adv Med Oncol 17:17588359251369038","journal-title":"Ther Adv Med Oncol"},{"key":"11516_CR10","first-page":"0765","volume":"8","author":"H Zhao","year":"2025","unstructured":"Zhao H, Ideker T, Wong STC (2025) Artificial Intelligence-Powered insights into polyclonality and tumor evolution. Res (Wash D C) 8:0765","journal-title":"Res (Wash D C)"},{"issue":"1","key":"11516_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41392-023-01500-w","volume":"8","author":"FJ Iborra","year":"2023","unstructured":"Iborra FJ et al (2023) Chemotherapy induces cell plasticity; controlling plasticity increases therapeutic response. Signal Transduct Target Ther 8(1):256","journal-title":"Signal Transduct Target Ther"},{"issue":"7654","key":"11516_CR12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature22323","volume":"545","author":"JS Lim","year":"2017","unstructured":"Lim JS et al (2017) Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer. Nature 545(7654):360\u2013364","journal-title":"Nature"},{"issue":"7","key":"11516_CR13","doi-asserted-by":"publisher","first-page":"E526","DOI":"10.21037\/jtd.2018.06.83","volume":"10","author":"S Shinohara","year":"2018","unstructured":"Shinohara S et al (2018) Squamous cell carcinoma transformation from adenocarcinoma as an acquired resistance after the EGFR TKI therapy in (EGFR-mutated) non-small cell lung cancer. J Thorac Dis 10(7):E526\u2013e531","journal-title":"J Thorac Dis"},{"issue":"8004","key":"11516_CR14","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41586-024-07113-9","volume":"627","author":"G Han","year":"2024","unstructured":"Han G et al (2024) An atlas of epithelial cell States and plasticity in lung adenocarcinoma. Nature 627(8004):656\u2013663","journal-title":"Nature"},{"issue":"1","key":"11516_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-024-01891-4","volume":"9","author":"J He","year":"2024","unstructured":"He J et al (2024) Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies. Signal Transduct Target Ther 9(1):209","journal-title":"Signal Transduct Target Ther"},{"issue":"4260","key":"11516_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1126\/science.959840","volume":"194","author":"PC Nowell","year":"1976","unstructured":"Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194(4260):23\u201328","journal-title":"Science"},{"issue":"4","key":"11516_CR17","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/cas.15674","volume":"114","author":"H Takahashi","year":"2023","unstructured":"Takahashi H et al (2023) Notch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small-cell lung cancer. Cancer Sci 114(4):1635\u20131650","journal-title":"Cancer Sci"},{"issue":"3","key":"11516_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/CAD.0000000000001686","volume":"36","author":"L Kuang","year":"2025","unstructured":"Kuang L et al (2025) Transformation of lung adenocarcinoma to small cell lung cancer following osimertinib treatment: a case report and literature review. Anticancer Drugs 36(3):253\u2013259","journal-title":"Anticancer Drugs"},{"key":"11516_CR19","doi-asserted-by":"crossref","unstructured":"Buus TB et al (2025) Divergent evolution of malignant subclones maintains a balance between induced aggressiveness and intrinsic drug resistance in T cell cancer. Cancer Discov","DOI":"10.1158\/2159-8290.30284435"},{"issue":"8005","key":"11516_CR20","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41586-024-07177-7","volume":"627","author":"J George","year":"2024","unstructured":"George J et al (2024) Evolutionary trajectories of small cell lung cancer under therapy. Nature 627(8005):880\u2013889","journal-title":"Nature"},{"issue":"1","key":"11516_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41392-024-01981-3","volume":"9","author":"Y Li","year":"2024","unstructured":"Li Y et al (2024) Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas. Signal Transduct Target Ther 9(1):261","journal-title":"Signal Transduct Target Ther"},{"issue":"50","key":"11516_CR22","doi-asserted-by":"publisher","first-page":"19914","DOI":"10.1073\/pnas.0707766104","volume":"104","author":"AR Wargo","year":"2007","unstructured":"Wargo AR et al (2007) Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model. Proc Natl Acad Sci U S A 104(50):19914\u201319919","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"11516_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41576-020-00299-4","volume":"22","author":"E Persi","year":"2021","unstructured":"Persi E et al (2021) Mutation-selection balance and compensatory mechanisms in tumour evolution. Nat Rev Genet 22(4):251\u2013262","journal-title":"Nat Rev Genet"},{"issue":"1","key":"11516_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41571-025-01085-z","volume":"23","author":"J Zhao","year":"2026","unstructured":"Zhao J et al (2026) Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches. Nat Rev Clin Oncol 23(1):63\u201383","journal-title":"Nat Rev Clin Oncol"},{"key":"11516_CR25","doi-asserted-by":"publisher","first-page":"107885","DOI":"10.1016\/j.lungcan.2024.107885","volume":"194","author":"M Izumi","year":"2024","unstructured":"Izumi M, Costa DB, Kobayashi SS (2024) Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer. Lung Cancer 194:107885","journal-title":"Lung Cancer"},{"issue":"4","key":"11516_CR26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jtho.2022.12.003","volume":"18","author":"N Moghal","year":"2023","unstructured":"Moghal N et al (2023) Single-Cell analysis reveals transcriptomic features of Drug-Tolerant persisters and stromal adaptation in a Patient-Derived EGFR-Mutated lung adenocarcinoma xenograft model. J Thorac Oncol 18(4):499\u2013515","journal-title":"J Thorac Oncol"},{"issue":"8","key":"11516_CR27","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41568-025-00824-9","volume":"25","author":"A Soragni","year":"2025","unstructured":"Soragni A et al (2025) Acquired resistance in cancer: towards targeted therapeutic strategies. Nat Rev Cancer 25(8):613\u2013633","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"11516_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma SV et al (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141(1):69\u201380","journal-title":"Cell"},{"issue":"8","key":"11516_CR29","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1158\/0008-5472.CAN-23-0438","volume":"84","author":"B Hu","year":"2024","unstructured":"Hu B et al (2024) ASCL1 drives tolerance to osimertinib in EGFR mutant lung cancer in permissive cellular contexts. Cancer Res 84(8):1303\u20131319","journal-title":"Cancer Res"},{"issue":"1","key":"11516_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10555-024-10172-z","volume":"43","author":"GR Bhat","year":"2024","unstructured":"Bhat GR et al (2024) Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. Cancer Metastasis Rev 43(1):197\u2013228","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"11516_CR31","first-page":"100623","volume":"5","author":"B Zhang","year":"2024","unstructured":"Zhang B et al (2024) Brief report: comprehensive clinicogenomic profiling of small cell transformation from EGFR-Mutant NSCLC informs potential therapeutic targets. JTO Clin Res Rep 5(2):100623","journal-title":"JTO Clin Res Rep"},{"issue":"4","key":"11516_CR32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.6004\/jnccn.2019.7291","volume":"17","author":"J Gong","year":"2019","unstructured":"Gong J et al (2019) Squamous cell transformation of primary lung adenocarcinoma in a patient with EML4-ALK fusion variant 5 refractory to ALK inhibitors. J Natl Compr Canc Netw 17(4):297\u2013301","journal-title":"J Natl Compr Canc Netw"},{"issue":"7973","key":"11516_CR33","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41586-023-06303-1","volume":"620","author":"H Isozaki","year":"2023","unstructured":"Isozaki H et al (2023) Therapy-induced APOBEC3A drives evolution of persistent cancer cells. Nature 620(7973):393\u2013401","journal-title":"Nature"},{"issue":"10","key":"11516_CR34","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nm.4409","volume":"23","author":"E Batlle","year":"2017","unstructured":"Batlle E, Clevers H (2017) Cancer stem cells revisited. Nat Med 23(10):1124\u20131134","journal-title":"Nat Med"},{"issue":"1","key":"11516_CR35","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","volume":"9","author":"X Chu","year":"2024","unstructured":"Chu X et al (2024) Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct Target Therapy 9(1):170","journal-title":"Signal Transduct Target Therapy"},{"issue":"8088","key":"11516_CR36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-025-09503-z","volume":"647","author":"AS Ireland","year":"2025","unstructured":"Ireland AS et al (2025) Basal cell of origin resolves neuroendocrine-tuft lineage plasticity in cancer. Nature 647(8088):257\u2013267","journal-title":"Nature"},{"issue":"11","key":"11516_CR37","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1016\/j.celrep.2020.02.052","volume":"30","author":"G Ferone","year":"2020","unstructured":"Ferone G et al (2020) FGFR1 oncogenic activation reveals an alternative cell of origin of SCLC in Rb1\/p53 mice. Cell Rep 30(11):3837\u20133850e3","journal-title":"Cell Rep"},{"issue":"1","key":"11516_CR38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41388-021-02070-3","volume":"41","author":"J Chen","year":"2022","unstructured":"Chen J et al (2022) Lineage-restricted neoplasia driven by Myc defaults to small cell lung cancer when combined with loss of p53 and Rb in the airway epithelium. Oncogene 41(1):138\u2013145","journal-title":"Oncogene"},{"issue":"6","key":"11516_CR39","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","volume":"17","author":"\u00c1 Quintanal-Villalonga","year":"2020","unstructured":"Quintanal-Villalonga \u00c1 et al (2020) Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol 17(6):360\u2013371","journal-title":"Nat Rev Clin Oncol"},{"issue":"8013","key":"11516_CR40","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41586-024-07377-1","volume":"629","author":"B Lin","year":"2024","unstructured":"Lin B et al (2024) Airway hillocks are injury-resistant reservoirs of unique plastic stem cells. Nature 629(8013):869\u2013877","journal-title":"Nature"},{"issue":"6524","key":"11516_CR41","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1126\/science.aba0629","volume":"371","author":"M Shivaraju","year":"2021","unstructured":"Shivaraju M et al (2021) Airway stem cells sense hypoxia and differentiate into protective solitary neuroendocrine cells. Science 371(6524):52\u201357","journal-title":"Science"},{"issue":"5","key":"11516_CR42","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1515\/jtim-2024-0019","volume":"12","author":"N Tan","year":"2024","unstructured":"Tan N et al (2024) Histological transformation in lung adenocarcinoma: insights of mechanisms and therapeutic windows. J Transl Int Med 12(5):452\u2013465","journal-title":"J Transl Int Med"},{"issue":"12","key":"11516_CR43","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1158\/2159-8290.CD-20-1863","volume":"11","author":"A Quintanal-Villalonga","year":"2021","unstructured":"Quintanal-Villalonga A et al (2021) Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation. Cancer Discov 11(12):3028\u20133047","journal-title":"Cancer Discov"},{"issue":"10","key":"11516_CR44","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","volume":"14","author":"M Offin","year":"2019","unstructured":"Offin M et al (2019) Concurrent RB1 and TP53 alterations define a subset of EGFR-Mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J Thorac Oncol 14(10):1784\u20131793","journal-title":"J Thorac Oncol"},{"issue":"1","key":"11516_CR45","doi-asserted-by":"publisher","first-page":"6377","DOI":"10.1038\/ncomms7377","volume":"6","author":"MJ Niederst","year":"2015","unstructured":"Niederst MJ et al (2015) RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun 6(1):6377","journal-title":"Nat Commun"},{"issue":"1","key":"11516_CR46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12964-023-01260-8","volume":"22","author":"X Ding","year":"2024","unstructured":"Ding X et al (2024) Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer. Cell Commun Signal 22(1):45","journal-title":"Cell Commun Signal"},{"issue":"8","key":"11516_CR47","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s00432-025-06283-x","volume":"151","author":"X Wu","year":"2025","unstructured":"Wu X et al (2025) Combined small-cell lung cancer with adenocarcinoma: a rare case and literatures review. J Cancer Res Clin Oncol 151(8):230","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"11516_CR48","doi-asserted-by":"publisher","first-page":"nwad028","DOI":"10.1093\/nsr\/nwad028","volume":"10","author":"S Tang","year":"2023","unstructured":"Tang S et al (2023) Counteracting lineage-specific transcription factor network finely tunes lung adeno-to-squamous transdifferentiation through remodeling tumor immune microenvironment. Natl Sci Rev 10(4):nwad028","journal-title":"Natl Sci Rev"},{"key":"11516_CR49","doi-asserted-by":"publisher","first-page":"637745","DOI":"10.3389\/pore.2021.637745","volume":"27","author":"Y Zhang","year":"2021","unstructured":"Zhang Y et al (2021) Case report: A case report of a histological transformation of ALK-Rearranged adenocarcinoma with high expression of PD-L1 to squamous cell carcinoma after treatment with alectinib. Pathol Oncol Res 27:637745","journal-title":"Pathol Oncol Res"},{"key":"11516_CR50","doi-asserted-by":"publisher","first-page":"942084","DOI":"10.3389\/fonc.2022.942084","volume":"12","author":"YZ Xi","year":"2022","unstructured":"Xi YZ et al (2022) Transformation of adenocarcinoma to squamous cell carcinoma as a source of EGFR-TKI resistance: A case report and literature review. Front Oncol 12:942084","journal-title":"Front Oncol"},{"issue":"1","key":"11516_CR51","doi-asserted-by":"publisher","first-page":"388","DOI":"10.21037\/tcr.2019.11.34","volume":"9","author":"Y Shao","year":"2020","unstructured":"Shao Y, Zhong DS, Guan SS (2020) Histologic transformation of lung adenocarcinoma to squamous cell carcinoma after chemotherapy: two case reports. Transl Cancer Res 9(1):388\u2013393","journal-title":"Transl Cancer Res"},{"issue":"10","key":"11516_CR52","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1016\/j.jtho.2019.05.039","volume":"14","author":"Y Kozuma","year":"2019","unstructured":"Kozuma Y et al (2019) Squamous cell carcinoma transformation as a possible resistant mechanism against pembrolizumab plus chemotherapy. J Thorac Oncol 14(10):e238\u2013e240","journal-title":"J Thorac Oncol"},{"key":"11516_CR53","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.lungcan.2020.10.013","volume":"150","author":"A Krause","year":"2020","unstructured":"Krause A et al (2020) Deciphering the clonal relationship between glandular and squamous components in adenosquamous carcinoma of the lung using whole exome sequencing. Lung Cancer 150:132\u2013138","journal-title":"Lung Cancer"},{"issue":"1","key":"11516_CR54","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1038\/s41467-025-59623-3","volume":"16","author":"T Shinozaki","year":"2025","unstructured":"Shinozaki T et al (2025) Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma. Nat Commun 16(1):4369","journal-title":"Nat Commun"},{"issue":"1","key":"11516_CR55","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13045-021-01186-z","volume":"14","author":"A Quintanal-Villalonga","year":"2021","unstructured":"Quintanal-Villalonga A et al (2021) Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. J Hematol Oncol 14(1):170","journal-title":"J Hematol Oncol"},{"issue":"3","key":"11516_CR56","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ccell.2024.01.012","volume":"42","author":"X Tong","year":"2024","unstructured":"Tong X et al (2024) Adeno-to-squamous transition drives resistance to KRAS Inhibition in LKB1 mutant lung cancer. Cancer Cell 42(3):413\u2013428 .e7","journal-title":"Cancer Cell"},{"issue":"1","key":"11516_CR57","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1016\/j.cllc.2017.10.005","volume":"19","author":"H Izumi","year":"2018","unstructured":"Izumi H et al (2018) Squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma: A case report and literature review. Clin Lung Cancer 19(1):e63\u2013e66","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"11516_CR58","first-page":"100639","volume":"5","author":"S Takahashi","year":"2024","unstructured":"Takahashi S et al (2024) Long-Term efficacy of immune checkpoint inhibitor for squamous cell carcinoma lesion transformed from EGFR-Mutated adenocarcinoma after osimertinib treatment: A case report. JTO Clin Res Rep 5(2):100639","journal-title":"JTO Clin Res Rep"},{"issue":"6","key":"11516_CR59","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41568-025-00803-0","volume":"25","author":"KL Simpson","year":"2025","unstructured":"Simpson KL et al (2025) Challenges of small cell lung cancer heterogeneity and phenotypic plasticity. Nat Rev Cancer 25(6):447\u2013462","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"11516_CR60","first-page":"734","volume":"24","author":"M Xu","year":"2021","unstructured":"Xu M et al (2021) [Advances in molecular typing of small cell lung Cancer]. Zhongguo Fei Ai Za Zhi 24(10):734\u2013738","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"5","key":"11516_CR61","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin CM et al (2019) Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer 19(5):289\u2013297","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"11516_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29517-9","volume":"13","author":"D Lissa","year":"2022","unstructured":"Lissa D et al (2022) Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models. Nat Commun 13(1):2023","journal-title":"Nat Commun"},{"issue":"1","key":"11516_CR63","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ccell.2020.05.001","volume":"38","author":"AS Ireland","year":"2020","unstructured":"Ireland AS et al (2020) MYC drives Temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate. Cancer Cell 38(1):60\u201378e12","journal-title":"Cancer Cell"},{"issue":"6","key":"11516_CR64","first-page":"948","volume":"55","author":"Y Jin","year":"2023","unstructured":"Jin Y et al (2023) Understanding SCLC heterogeneity and plasticity in cancer metastasis and chemotherapy resistance. Acta Biochim Biophys Sin (Shanghai) 55(6):948\u2013955","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"4","key":"11516_CR65","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1200\/JCO.18.01585","volume":"37","author":"N Marcoux","year":"2019","unstructured":"Marcoux N et al (2019) EGFR-Mutant adenocarcinomas that transform to Small-Cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol 37(4):278\u2013285","journal-title":"J Clin Oncol"},{"key":"11516_CR66","doi-asserted-by":"crossref","unstructured":"Li Q et al (2024) Rare case report: a case of histological type transformation of lung cancer caused by neoadjuvant immunotherapy. Front Oncol, Volume 14\u20132024","DOI":"10.3389\/fonc.2024.1329152"},{"issue":"6","key":"11516_CR67","doi-asserted-by":"publisher","first-page":"Np15","DOI":"10.1177\/03008916221080487","volume":"108","author":"A Mariniello","year":"2022","unstructured":"Mariniello A et al (2022) Squamous cell histological transformation in a lung adenocarcinoma patient (hyper) progressing upon immunotherapy. Tumori 108(6):Np15-np19","journal-title":"Tumori"},{"issue":"3","key":"11516_CR68","doi-asserted-by":"publisher","first-page":"637","DOI":"10.21037\/tlcr-23-154","volume":"12","author":"G Xia","year":"2023","unstructured":"Xia G et al (2023) Transformation of ALK-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case report. Transl Lung Cancer Res 12(3):637\u2013646","journal-title":"Transl Lung Cancer Res"},{"key":"11516_CR69","doi-asserted-by":"publisher","first-page":"107415","DOI":"10.1016\/j.lungcan.2023.107415","volume":"186","author":"X Lingling","year":"2023","unstructured":"Lingling X et al (2023) Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review. Lung Cancer 186:107415","journal-title":"Lung Cancer"},{"issue":"11","key":"11516_CR70","doi-asserted-by":"publisher","first-page":"e32030","DOI":"10.1016\/j.heliyon.2024.e32030","volume":"10","author":"Q He","year":"2024","unstructured":"He Q et al (2024) Changing ALK-TKI mechanisms of resistance in re-biopsies of ALK-rearranged NSCLC: ALK mutations followed by SCLC-like histologic transformation: A case report. Heliyon 10(11):e32030","journal-title":"Heliyon"},{"key":"11516_CR71","doi-asserted-by":"publisher","first-page":"p110","DOI":"10.1016\/j.lungcan.2017.02.005","volume":"106","author":"SI Ou","year":"2017","unstructured":"Ou SI et al (2017) Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy? Lung Cancer 106:p110\u2013114","journal-title":"Lung Cancer"},{"key":"11516_CR72","doi-asserted-by":"publisher","first-page":"1308313","DOI":"10.3389\/fonc.2023.1308313","volume":"13","author":"Y Chen","year":"2023","unstructured":"Chen Y et al (2023) Clinical and molecular profiling of EGFR-mutant lung adenocarcinomas transformation to small cell lung cancer during TKI treatment. Front Oncol 13:1308313","journal-title":"Front Oncol"},{"issue":"6","key":"11516_CR73","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/15384047.2018.1435222","volume":"19","author":"Y Liu","year":"2018","unstructured":"Liu Y (2018) Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: a case report and literatures review. Cancer Biol Ther 19(6):445\u2013449","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"11516_CR74","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/1759-7714.14832","volume":"14","author":"L Hao","year":"2023","unstructured":"Hao L et al (2023) Transformation or tumor heterogeneity: mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer. Thorac Cancer 14(11):1036\u20131041","journal-title":"Thorac Cancer"},{"key":"11516_CR75","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.lungcan.2017.11.011","volume":"115","author":"R Minari","year":"2018","unstructured":"Minari R et al (2018) Primary resistance to osimertinib due to SCLC transformation: issue of T790M determination on liquid re-biopsy. Lung Cancer 115:21\u201327","journal-title":"Lung Cancer"},{"key":"11516_CR76","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.lungcan.2021.03.006","volume":"155","author":"W Wang","year":"2021","unstructured":"Wang W et al (2021) Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study. Lung Cancer 155:20\u201327","journal-title":"Lung Cancer"},{"key":"11516_CR77","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.lungcan.2016.11.012","volume":"103","author":"L Longo","year":"2017","unstructured":"Longo L et al (2017) Synchronous occurrence of squamous-cell carcinoma transformation and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma. Lung Cancer 103:24\u201326","journal-title":"Lung Cancer"},{"issue":"1","key":"11516_CR78","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jtho.2018.08.2028","volume":"14","author":"L Ferrer","year":"2019","unstructured":"Ferrer L et al (2019) A brief report of transformation from NSCLC to SCLC: molecular and therapeutic characteristics. J Thorac Oncol 14(1):130\u2013134","journal-title":"J Thorac Oncol"},{"key":"11516_CR79","first-page":"85","volume":"9","author":"N Abdallah","year":"2018","unstructured":"Abdallah N et al (2018) Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation. Lung Cancer (Auckl) 9:85\u201390","journal-title":"Lung Cancer (Auckl)"},{"issue":"22","key":"11516_CR80","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1111\/1759-7714.14180","volume":"12","author":"T Imakita","year":"2021","unstructured":"Imakita T et al (2021) Small cell transformation of non-small cell lung cancer under immunotherapy: case series and literature review. Thorac Cancer 12(22):3062\u20133067","journal-title":"Thorac Cancer"},{"key":"11516_CR81","doi-asserted-by":"publisher","first-page":"619371","DOI":"10.3389\/fonc.2021.619371","volume":"11","author":"Q Shen","year":"2021","unstructured":"Shen Q et al (2021) Case report: transformation from Non-Small cell lung cancer to small cell lung cancer during Anti-PD-1 therapy: A report of two cases. Front Oncol 11:619371","journal-title":"Front Oncol"},{"issue":"6","key":"11516_CR82","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/j.jtho.2017.02.006","volume":"12","author":"CL Hsu","year":"2017","unstructured":"Hsu CL et al (2017) Histologic transformation in a patient with lung cancer treated with chemotherapy and pembrolizumab. J Thorac Oncol 12(6):e75\u2013e76","journal-title":"J Thorac Oncol"},{"issue":"9","key":"11516_CR83","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/2159-8290.CD-24-1866","volume":"15","author":"I Vathiotis","year":"2025","unstructured":"Vathiotis I et al (2025) Histologic transformation in cancer: the path for clinical translation. Cancer Discov 15(9):1783\u20131793","journal-title":"Cancer Discov"},{"issue":"7","key":"11516_CR84","doi-asserted-by":"publisher","first-page":"105326","DOI":"10.1016\/j.esmoop.2025.105326","volume":"10","author":"C Catania","year":"2025","unstructured":"Catania C et al (2025) Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study. ESMO Open 10(7):105326","journal-title":"ESMO Open"},{"key":"11516_CR85","doi-asserted-by":"publisher","first-page":"115065","DOI":"10.1016\/j.ejca.2024.115065","volume":"213","author":"FC Saalfeld","year":"2024","unstructured":"Saalfeld FC et al (2024) Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy. Eur J Cancer 213:115065","journal-title":"Eur J Cancer"},{"key":"11516_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32100554","author":"A Rock","year":"2025","unstructured":"Rock A et al (2025) Small cell transformation of EGFR-mutant NSCLC treated with tyrosine kinase inhibition. Curr Oncol 32(10):554.","journal-title":"Curr Oncol"},{"issue":"17","key":"11516_CR87","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.1158\/1078-0432.CCR-24-0466","volume":"30","author":"T El Zarif","year":"2024","unstructured":"El Zarif T et al (2024) Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic CfDNA profiling. Clin Cancer Res 30(17):3798\u20133811","journal-title":"Clin Cancer Res"},{"key":"11516_CR88","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.65824","author":"I Galdadas","year":"2021","unstructured":"Galdadas I et al (2021) Structural basis of the effect of activating mutations on the EGF receptor. Elife 10: e65824","journal-title":"Elife"},{"issue":"1","key":"11516_CR89","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41467-020-20839-0","volume":"12","author":"I Hwang","year":"2021","unstructured":"Hwang I et al (2021) Cellular stress signaling activates type-I IFN response through FOXO3-regulated lamin posttranslational modification. Nat Commun 12(1):640","journal-title":"Nat Commun"},{"issue":"1","key":"11516_CR90","doi-asserted-by":"publisher","first-page":"7879","DOI":"10.1038\/s41467-024-51794-9","volume":"15","author":"L Santini","year":"2024","unstructured":"Santini L et al (2024) FoxO transcription factors actuate the formative pluripotency specific gene expression programme. Nat Commun 15(1):7879","journal-title":"Nat Commun"},{"key":"11516_CR91","doi-asserted-by":"publisher","first-page":"106025","DOI":"10.1016\/j.ebiom.2025.106025","volume":"122","author":"F Wu","year":"2025","unstructured":"Wu F et al (2025) A unified single-cell atlas of human lung provides insights into pulmonary diseases. EBioMedicine 122:106025","journal-title":"EBioMedicine"},{"issue":"22","key":"11516_CR92","doi-asserted-by":"publisher","first-page":"e2101999","DOI":"10.1002\/advs.202101999","volume":"8","author":"F Chen","year":"2021","unstructured":"Chen F et al (2021) Cellular origins of EGFR-Driven lung cancer cells determine sensitivity to therapy. Adv Sci (Weinh) 8(22):e2101999","journal-title":"Adv Sci (Weinh)"},{"key":"11516_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112998","author":"SL Feldt","year":"2023","unstructured":"Feldt SL, Bestvina CM (2023) The role of MET in resistance to EGFR inhibition in NSCLC: a review of mechanisms and treatment implications. Cancers (Basel) 15(11):2998","journal-title":"Cancers (Basel)"},{"issue":"3","key":"11516_CR94","doi-asserted-by":"publisher","first-page":"e472784","DOI":"10.1200\/EDBK-25-472784","volume":"45","author":"G La Cava","year":"2025","unstructured":"La Cava G et al (2025) Navigating First-Line treatment options for patients with epidermal growth factor Receptor-Positive Non-Small cell lung cancer. Am Soc Clin Oncol Educ Book 45(3):e472784","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"11","key":"11516_CR95","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.annonc.2020.08.2100","volume":"31","author":"VA Papadimitrakopoulou","year":"2020","unstructured":"Papadimitrakopoulou VA et al (2020) Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol 31(11):1536\u20131544","journal-title":"Ann Oncol"},{"key":"11516_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225599","author":"HJ Kim","year":"2021","unstructured":"Kim HJ et al (2021) Oncogenic KRAS: signaling and drug resistance. Cancers (Basel) 13(22):5599","journal-title":"Cancers (Basel)"},{"issue":"6","key":"11516_CR97","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1158\/2159-8290.CD-18-1220","volume":"9","author":"EJ Poulin","year":"2019","unstructured":"Poulin EJ et al (2019) Tissue-Specific oncogenic activity of KRAS(A146T). Cancer Discov 9(6):738\u2013755","journal-title":"Cancer Discov"},{"issue":"1","key":"11516_CR98","doi-asserted-by":"publisher","first-page":"7080","DOI":"10.1038\/s41467-025-62350-4","volume":"16","author":"JC \u00c1lvarez-P\u00e9rez","year":"2025","unstructured":"\u00c1lvarez-P\u00e9rez JC et al (2025) High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models. Nat Commun 16(1):7080","journal-title":"Nat Commun"},{"issue":"7971","key":"11516_CR99","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/s41586-023-06324-w","volume":"619","author":"NH Juul","year":"2023","unstructured":"Juul NH et al (2023) KRAS(G12D) drives lepidic adenocarcinoma through stem-cell reprogramming. Nature 619(7971):860\u2013867","journal-title":"Nature"},{"issue":"11","key":"11516_CR100","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1158\/2767-9764.CRC-22-0408","volume":"3","author":"P Chaudhary","year":"2023","unstructured":"Chaudhary P et al (2023) Activation of KrasG12D in subset of alveolar type II cells enhances cellular plasticity in lung adenocarcinoma. Cancer Res Commun 3(11):2400\u20132411","journal-title":"Cancer Res Commun"},{"issue":"1","key":"11516_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41417-023-00687-y","volume":"31","author":"SM Lenahan","year":"2024","unstructured":"Lenahan SM et al (2024) STK11 loss leads to YAP1-mediated transcriptional activation in human KRAS-driven lung adenocarcinoma cell lines. Cancer Gene Ther 31(1):1\u20138","journal-title":"Cancer Gene Ther"},{"key":"11516_CR102","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1038\/ncomms5629","volume":"5","author":"Y Gao","year":"2014","unstructured":"Gao Y et al (2014) YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression. Nat Commun 5:4629","journal-title":"Nat Commun"},{"issue":"1","key":"11516_CR103","doi-asserted-by":"publisher","first-page":"15007","DOI":"10.1038\/s41598-024-65945-x","volume":"14","author":"L Acero-Riaguas","year":"2024","unstructured":"Acero-Riaguas L et al (2024) DUSP1 and SOX2 expression determine squamous cell carcinoma of the salivary gland progression. Sci Rep 14(1):15007","journal-title":"Sci Rep"},{"issue":"17","key":"11516_CR104","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1101\/gad.243717.114","volume":"28","author":"X Xu","year":"2014","unstructured":"Xu X et al (2014) The cell of origin and subtype of K-Ras-induced lung tumors are modified by Notch and Sox2. Genes Dev 28(17):1929\u20131939","journal-title":"Genes Dev"},{"issue":"17","key":"11516_CR105","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.1158\/0008-5472.CAN-19-0161","volume":"79","author":"Y Wang","year":"2019","unstructured":"Wang Y et al (2019) Dysregulated Tgfbr2\/ERK-Smad4\/SOX2 signaling promotes lung squamous cell carcinoma formation. Cancer Res 79(17):4466\u20134479","journal-title":"Cancer Res"},{"issue":"11","key":"11516_CR106","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.21037\/tlcr-21-536","volume":"10","author":"H Koba","year":"2021","unstructured":"Koba H et al (2021) NOTCH alteration in EGFR-mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment. Transl Lung Cancer Res 10(11):4161\u20134173","journal-title":"Transl Lung Cancer Res"},{"issue":"45","key":"11516_CR107","doi-asserted-by":"publisher","first-page":"4960","DOI":"10.1038\/s41388-022-02458-9","volume":"41","author":"DK Sullivan","year":"2022","unstructured":"Sullivan DK et al (2022) MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes. Oncogene 41(45):4960\u20134970","journal-title":"Oncogene"},{"issue":"7","key":"11516_CR108","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1158\/2159-8290.CD-22-0620","volume":"13","author":"S Sivakumar","year":"2023","unstructured":"Sivakumar S et al (2023) Integrative analysis of a large Real-World cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histologic transformation. Cancer Discov 13(7):1572\u20131591","journal-title":"Cancer Discov"},{"key":"11516_CR109","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc2578","author":"AS Patel","year":"2021","unstructured":"Patel AS et al (2021) Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer. Sci Adv 7(5): eabc2578","journal-title":"Sci Adv"},{"issue":"5","key":"11516_CR110","doi-asserted-by":"publisher","first-page":"115617","DOI":"10.1016\/j.celrep.2025.115617","volume":"44","author":"E Lacroix","year":"2025","unstructured":"Lacroix E et al (2025) PI3K\/AKT signaling mediates stress-inducible amyloid formation through c-Myc. Cell Rep 44(5):115617","journal-title":"Cell Rep"},{"issue":"12","key":"11516_CR111","doi-asserted-by":"publisher","first-page":"102513","DOI":"10.1016\/j.xcrm.2025.102513","volume":"6","author":"Y Chen","year":"2025","unstructured":"Chen Y et al (2025) Lung adenocarcinoma surfaceome remodeling with EGFR inhibitors uncovers placental alkaline phosphatase as a target for combination therapy. Cell Rep Med 6(12):102513","journal-title":"Cell Rep Med"},{"issue":"707","key":"11516_CR112","doi-asserted-by":"publisher","first-page":"eadf7006","DOI":"10.1126\/scitranslmed.adf7006","volume":"15","author":"A Quintanal-Villalonga","year":"2023","unstructured":"Quintanal-Villalonga A et al (2023) Exportin 1 Inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers. Sci Transl Med 15(707):eadf7006","journal-title":"Sci Transl Med"},{"key":"11516_CR113","doi-asserted-by":"publisher","first-page":"1542526","DOI":"10.3389\/fimmu.2025.1542526","volume":"16","author":"H Xu","year":"2025","unstructured":"Xu H et al (2025) Unraveling the immune mechanisms and therapeutic targets in lung adenosquamous transformation. Front Immunol 16:1542526","journal-title":"Front Immunol"},{"issue":"4","key":"11516_CR114","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.asjsur.2022.01.055","volume":"45","author":"SB Lu","year":"2022","unstructured":"Lu SB et al (2022) Adenosquamous carcinoma of sigmoid colon in an adolescent: A case report and literature review. Asian J Surg 45(4):1055\u20131056","journal-title":"Asian J Surg"},{"issue":"12","key":"11516_CR115","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1158\/1541-7786.MCR-20-1006","volume":"19","author":"E Voigt","year":"2021","unstructured":"Voigt E et al (2021) Sox2 is an oncogenic driver of Small-Cell lung cancer and promotes the classic neuroendocrine subtype. Mol Cancer Res 19(12):2015\u20132025","journal-title":"Mol Cancer Res"},{"issue":"5","key":"11516_CR116","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.ccell.2025.03.027","volume":"43","author":"M Teng","year":"2025","unstructured":"Teng M et al (2025) Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation. Cancer Cell 43(5):891\u2013904e10","journal-title":"Cancer Cell"},{"issue":"3","key":"11516_CR117","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jtho.2022.11.019","volume":"18","author":"L Zhang","year":"2023","unstructured":"Zhang L et al (2023) PTEN loss expands the histopathologic diversity and lineage plasticity of lung cancers initiated by Rb1\/Trp53 deletion. J Thorac Oncol 18(3):324\u2013338","journal-title":"J Thorac Oncol"},{"issue":"2","key":"11516_CR118","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2767-9764.CRC-23-0399","volume":"4","author":"TJ DuCote","year":"2024","unstructured":"DuCote TJ et al (2024) EZH2 Inhibition promotes tumor immunogenicity in lung squamous cell carcinomas. Cancer Res Commun 4(2):388\u2013403","journal-title":"Cancer Res Commun"},{"key":"11516_CR119","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.171364","author":"N Sengottuvel","year":"2025","unstructured":"Sengottuvel N et al (2025) Tumor suppressors in Sox2-mediated lung cancers promote distinct cell-intrinsic and immunologic remodeling. JCI Insight 10(12): e171364","journal-title":"JCI Insight"},{"key":"11516_CR120","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejca.2021.01.050","volume":"148","author":"N Krishnamurthy","year":"2021","unstructured":"Krishnamurthy N et al (2021) STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications. Eur J Cancer 148:215\u2013229","journal-title":"Eur J Cancer"},{"issue":"1","key":"11516_CR121","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41392-022-01227-0","volume":"8","author":"Z Fang","year":"2023","unstructured":"Fang Z et al (2023) Oxidative stress-triggered Wnt signaling perturbation characterizes the tipping point of lung adeno-to-squamous transdifferentiation. Signal Transduct Target Ther 8(1):16","journal-title":"Signal Transduct Target Ther"},{"key":"11516_CR122","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1038\/ncomms4261","volume":"5","author":"X Han","year":"2014","unstructured":"Han X et al (2014) Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. Nat Commun 5:3261","journal-title":"Nat Commun"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11516-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11516-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11516-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T14:03:14Z","timestamp":1770213794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11516-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":122,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11516"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11516-4","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"This is a review study. The Ethics Committee has confirmed that no ethical approval is required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"362"}}